Cardio-Oncology

Cancer survivorship has produced a growing cohort of patients with increased cardiovascular complications due to their cancer therapy. In response, the field of cardio-oncology has emerged as an integral component of oncologic patient care committed to the early diagnosis and treatment of adverse cardiac events.

Course ID: Q00589 Category:
Modalities: , , , , , ,

2.5

Satisfaction Guarantee

$29.00

View cart

Targeted CE per ARRT’s Discipline, Category, and Subcategory classification:
[Note: Discipline-specific Targeted CE credits may be less than the total Category A credits approved for this course.]

Nuclear Medicine Technology: 0.50
Procedures: 0.50
Cardiac Procedures: 0.50

Registered Radiologist Assistant: 2.50
Safety: 2.50
Patient Safety, Radiation Protection and Equipment Operation: 2.50

Outline

  1. Introduction
  2. Background
  3. Panomics: Biomarker Identification
    1. Genomics
    2. Proteomics
  4. Phenomapping with Imaging
    1. LVEF
    2. Myocardial Deformation and Mechanics
    3. CMR Imaging Metrics
    4. Myocardial Perfusion Imaging
    5. Cardiovascular Molecular Imaging Techniques
  5. Radiation-Induced Cardiotoxicity
    1. Radiation-Induced Atherosclerosis
  6. Conclusion

Objectives

Upon completion of this course, students will:

  1. know the name of the process of computational integration of clinical data with advanced genetic, biomolecular, and demographic profiling to better risk-stratify patients
  2. know the assumption that remains the current therapeutic standard in cancer therapy related CVD
  3. know the various categories of cardiovascular complications of cancer therapy listed in the article
  4. be familiar with the types of various traditional and targeted cancer therapies
  5. know the current recommendations for managing potential cardiac dysfunction in patients receiving cardiotoxic therapies
  6. know the signs and symptoms of the heart failure staging system
  7. identify what can currently be adjusted in the clinical management of cancer therapy cardiotoxicity, without the benefits of cardio-oncology precision medicine
  8. know where recent research has focused to complement sensitive imaging metrics
  9. understand why brain natriuretic peptide and troponin have not been more commonly used in cardio-oncology assessments
  10. be familiar with some potentially useful biomarkers that play critical roles in oxidative stress or nitric oxide metabolism which are potential mechanisms of anthracycline-induced cardiotoxicity
  11. know what can illuminate novel disease metrics in therapy-induced cardiotoxicity that can, in turn, inform cardio-oncology personalization
  12. know how precision phenotyping improves current cardio-oncology approaches
  13. be familiar with the cardiomyopathy risk and cardiotoxicity findings of various child and adult cancer survivor studies
  14. understand the significance and usefulness of circulating micro-RNA in CVD research
  15. understand the importance of energy metabolism in relation to daunorubicin-induced cardiotoxicity
  16. be familiar with the uses and insights into CVD that can be gleaned from metabolomics
  17. recognize the future potential of metabolomics studies and resulting data
  18. know the reasons that limit LVEF as a gold standard for the surveillance and diagnosis of treatment-related CVD
  19. know the reasons why 2D echocardiography is typically the modality of choice for LVEF measurement
  20. know why routine clinical use of 3D echocardiography has been challenging
  21. identify the factors that have limited the use of multi-gated acquisition for surveillance and diagnosis of treatment-related CVD
  22. know the major appeal of using imaging to measure myocardial deformation
  23. be familiar with the advantages of 3D STE imaging
  24. know how CMR T1-weighted images and T1 mapping can characterize cardiac tissue
  25. be familiar with CMR’s role in assessing cardiac function and blood flow
  26. be familiar with the SPECT-based study results in patients receiving left breast/chest wall RT compared with pre-RT SPECT scans
  27. know the features of PET myocardial perfusion imaging that make it the gold standard for myocardial perfusion assessment when compared with SPECT
  28. understand the challenges that have limited the use of PET imaging techniques in cardio-oncology patients
  29. be familiar with the various molecular imaging radiotracers, their molecular target or mechanism of uptake, and cardiovascular application
  30. be familiar with the canine model of radiation-induced cardiotoxicity, as cited in the article
  31. recognize the early markers of cardiotoxicity being utilized by new molecular imaging agents
  32. know the factor to which radiation therapy toxicity can be directly linked
  33. know a proposed therapeutic approach for radiation-induced cardiotoxicity that uses gene-expression assays to identify potential single-nucleotide polymorphisms that may predict adverse reactions to radiation therapy
  34. know how molecular imaging could be used as an early diagnosis and surveillance approach for radiation-induced atherosclerosis
  35. be familiar with the various imaging techniques associated with radiation-induced atherosclerosis